Bullous Pemphygoid and Novel Therapeutic Approaches
Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately. Although it is a rare disease, bullous pemphigoid is the most common among the autoimmune bullous skin diseases. Systemic corticosteroids...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/11/2844 |
| _version_ | 1797468989764403200 |
|---|---|
| author | Giovanni Marco D’Agostino Giulio Rizzetto Andrea Marani Samuele Marasca Matteo Candelora Daisy Gambini Helena Gioacchini Edoardo De Simoni Andrea Maurizi Anna Campanati Annamaria Offidani |
| author_facet | Giovanni Marco D’Agostino Giulio Rizzetto Andrea Marani Samuele Marasca Matteo Candelora Daisy Gambini Helena Gioacchini Edoardo De Simoni Andrea Maurizi Anna Campanati Annamaria Offidani |
| author_sort | Giovanni Marco D’Agostino |
| collection | DOAJ |
| description | Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately. Although it is a rare disease, bullous pemphigoid is the most common among the autoimmune bullous skin diseases. Systemic corticosteroids and immunosuppressants represent milestones in the treatment of patients suffering from bullous pemphigoid; however, therapeutic management of patients still represents a clinical challenge, owing to the chronic nature of the disease and to potential adverse effects related to the long-term use of systemic treatments. Recent discoveries on the pathogenesis of bullous pemphigoid have allowed investigation of new target therapies against selective pro-inflammatory mediators. These therapies appear to yield satisfactory results with fewer side effects in cases of refractory disease. The review discusses current evidence on these new therapeutic targets and specific drugs under investigation. |
| first_indexed | 2024-03-09T19:15:06Z |
| format | Article |
| id | doaj.art-55c61dcc354e45cb8de4a9e36837fac6 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T19:15:06Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-55c61dcc354e45cb8de4a9e36837fac62023-11-24T03:51:39ZengMDPI AGBiomedicines2227-90592022-11-011011284410.3390/biomedicines10112844Bullous Pemphygoid and Novel Therapeutic ApproachesGiovanni Marco D’Agostino0Giulio Rizzetto1Andrea Marani2Samuele Marasca3Matteo Candelora4Daisy Gambini5Helena Gioacchini6Edoardo De Simoni7Andrea Maurizi8Anna Campanati9Annamaria Offidani10Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, ItalyBullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately. Although it is a rare disease, bullous pemphigoid is the most common among the autoimmune bullous skin diseases. Systemic corticosteroids and immunosuppressants represent milestones in the treatment of patients suffering from bullous pemphigoid; however, therapeutic management of patients still represents a clinical challenge, owing to the chronic nature of the disease and to potential adverse effects related to the long-term use of systemic treatments. Recent discoveries on the pathogenesis of bullous pemphigoid have allowed investigation of new target therapies against selective pro-inflammatory mediators. These therapies appear to yield satisfactory results with fewer side effects in cases of refractory disease. The review discusses current evidence on these new therapeutic targets and specific drugs under investigation.https://www.mdpi.com/2227-9059/10/11/2844bullous pemphigoidtarget therapiesbiologicssmall moleculesnovel treatments |
| spellingShingle | Giovanni Marco D’Agostino Giulio Rizzetto Andrea Marani Samuele Marasca Matteo Candelora Daisy Gambini Helena Gioacchini Edoardo De Simoni Andrea Maurizi Anna Campanati Annamaria Offidani Bullous Pemphygoid and Novel Therapeutic Approaches Biomedicines bullous pemphigoid target therapies biologics small molecules novel treatments |
| title | Bullous Pemphygoid and Novel Therapeutic Approaches |
| title_full | Bullous Pemphygoid and Novel Therapeutic Approaches |
| title_fullStr | Bullous Pemphygoid and Novel Therapeutic Approaches |
| title_full_unstemmed | Bullous Pemphygoid and Novel Therapeutic Approaches |
| title_short | Bullous Pemphygoid and Novel Therapeutic Approaches |
| title_sort | bullous pemphygoid and novel therapeutic approaches |
| topic | bullous pemphigoid target therapies biologics small molecules novel treatments |
| url | https://www.mdpi.com/2227-9059/10/11/2844 |
| work_keys_str_mv | AT giovannimarcodagostino bullouspemphygoidandnoveltherapeuticapproaches AT giuliorizzetto bullouspemphygoidandnoveltherapeuticapproaches AT andreamarani bullouspemphygoidandnoveltherapeuticapproaches AT samuelemarasca bullouspemphygoidandnoveltherapeuticapproaches AT matteocandelora bullouspemphygoidandnoveltherapeuticapproaches AT daisygambini bullouspemphygoidandnoveltherapeuticapproaches AT helenagioacchini bullouspemphygoidandnoveltherapeuticapproaches AT edoardodesimoni bullouspemphygoidandnoveltherapeuticapproaches AT andreamaurizi bullouspemphygoidandnoveltherapeuticapproaches AT annacampanati bullouspemphygoidandnoveltherapeuticapproaches AT annamariaoffidani bullouspemphygoidandnoveltherapeuticapproaches |